The Light-er Side of Treating Seasonal Affective Disorder

October 1, 2005
Daniel M. Blumberger, MD, MSc

,
Anthony J. Levitt, MD, MBBS, FRCPC

Volume 22, Issue 11

Seasonal affective disorder affects 1% to 3% of the North American population. Evidence exists for the efficacy of high-intensity bright, fluorescent light. Pharmacological management with SSRIs has shown equivalent efficacy to light therapy. How can these two therapies be combined? What other therapies are available?

Rosenthal et al. (1984) first described seasonal affective disorder (SAD) as a pattern of recurrent depressions with a winter onset and a full remission the following summer. The emergence of treatment, specifically light therapy, was met with a mixture of enthusiasm and cautious skepticism. However, there is now substantial evidence to support its efficacy. This paper will review the treatment of SAD with a focus on new developments in the area.

The clinical presentation of SAD frequently includes the prominence of reverse vegetative or atypical symptoms (Rosenthal et al., 1984). Of these symptoms, increased appetite, carbohydrate craving, weight gain and hypersomnia are most commonly reported in large samples of patients with SAD. Prevalence estimates suggest that the condition occurs in 1% to 3% of the North American population (Blazer et al., 1998; Levitt and Boyle, 2002) with a female to male sex ratio of 1.6:1 (Lam and Levitt, 1999). Although initial research seemed to suggest a high frequency of bipolar disorders among patients with SAD (Rosenthal et al., 1987; Thompson and Isaacs, 1988), this has not been confirmed in subsequent reports (Levitt and Boyle, 2002; Thalen et al., 1995; Wehr et al., 1991).

The etiology and pathophysiology of SAD are still unknown; however, various hypotheses have garnered prominence in the literature. Most notably among these hypotheses is the theory of a dysregulated circadian rhythm, causing a phase delay (Lewy and Sack, 1988). This theory has been supported by evidence that early-morning light therapy is superior to evening light therapy (Eastman et al., 1998; Lewy et al., 1998b; Terman et al., 1998).

Another pathophysiological explanation for SAD is the evidence that suggests a disruption of serotonergic neurotransmission. Human and postmortem studies suggest that serotonin metabolism is decreased during winter months (Brewerton et al., 1988). Further support for the serotonergic hypothesis derives from studies with selective serotonin reuptake inhibitors (Lam et al., 1995; Moscovitch et al., 2004) and the precipitation of depression in patients with SAD during tryptophan depletion studies (Lam et al., 1996; Neumeister et al., 1997). Specific candidate genes affecting the serotonin system have been examined, but the evidence is still mixed (Johansson et al., 2001; Rosenthal et al., 1998).

Other investigators have proposed other possible mechanisms including the role of melatonin (Rosenthal et al., 1988), the photoperiod and latitudinal variation (Levitt and Boyle, 2002; Rosen et al., 1990), and the roles of other neurotransmitters (Oren et al., 1994; Rudorfer et al., 1993). However, there appears to be no single mechanism that can explain the syndrome entirely at this point in time.

Light Therapy

Light therapy is an effective first-line treatment for SAD. It has proven effectiveness compared to psychopharmacological treatments and to various placebo controls. The basic parameters of treatment include intensity, wavelength, duration of daily exposure and timing of light exposure. Benefits of treatment are usually seen within two to seven days, and the response rate ranges from 60% to 90% (Lam and Levitt, 1999). Bright light treatment with a fluorescent light box (minimum 2,500 lux) has been most widely studied and its benefits more firmly validated than other modalities. However, there is some evidence for the use of head-mounted units (HMUs) (Levitt et al., 1996; Meesters et al., 1999) and dawn simulators (Avery et al., 2001). A recent meta-analysis, including the eight most rigorous studies of fluorescent light box therapy, found an effect size of 0.84 (95% confidence interval, 0.60 to 1.08) (Golden et al., 2005). This is similar, if not superior, to the treatment effect sizes found in nonseasonal depression.

Various HMUs have been developed. These units may use either fluorescent, halogen or LED light sources. The practical advantage to using HMUs is that patients can move about freely while having their treatment. Most studies of HMUs have failed to show a benefit over placebo, although response rates have been in the range of 60% to 70% (Joffe et al., 1993). Dawn simulation involves the administration of lower-intensity light (max 250 lux) in the 30 to 90 minutes prior to rising in the morning. There have been five well-designed studies demonstrating the effectiveness of dawn simulation, all from the same research group (Avery et al., 2001).

Individuals with clear recurrent winter depressions with full summer remissions and the presence of reverse vegetative symptoms respond best to bright light therapy (Levitan, 2005). In addition, situations where pharmacological intervention is risky should warrant the consideration of bright light therapy. Insurers may not cover the expense of a light therapy device; therefore, clinicians must be cognizant that cost of a unit ranges between $250 and $450 (Lam and Levitt, 1999). Ultraviolet light can be damaging to the eyes, therefore, ultraviolet light filters should be used (Lam et al., 1992). If there is a pre-existing history of ophthalmologic conditions, systemic illnesses affecting the retina or concurrent use of a photosensitizing medication (e.g., lithium [Eskalith, Lithobid], chloroquine [Aralen], phenothiazine [Phenerzine], melatonin, hypericum, 8-methoxypsoralen), patients should be referred to an ophthalmologist for baseline screening and routine monitoring (Lam and Levitt, 1999). Clinicians need to be aware of the potential risk of induction of hypomania or mania in patients with a bipolar diathesis (Bauer et al., 1994; Chan et al., 1994).

To maximize compliance and practicality, light therapy should be initiated with a fluorescent light box that delivers an intensity of 10,000 lux for a half hour as soon as possible upon awakening and before 10 a.m. The patient should position the light box according to the manufacturer's instruction and use it the same time each day as much as possible.

The side effects of light therapy are minimal (Table) (Levitt et al., 1993). If patients are unable to tolerate the treatment due to agitation, headache or nausea, the intensity of the treatment can be reduced by increasing the distance from the light box or changing the duration of therapy.

Treatment response to light therapy can be rapid, starting with two to four days (Lam and Levitt, 1999). Most studies have been of short duration, although some investigators have suggested that four weeks of treatment may be optimal (Eastman et al., 1998; Ruhrmann et al., 1998). As relapse rates are high after discontinuation, maintenance of treatment through the winter season should be considered. There is also evidence that suggested relapse can be prevented with the addition of citalopram (Celexa) after response to a course of light therapy (Martiny et al., 2004). The use of dawn simulation and HMUs should be considered a second-line option.

Pharmacotherapy

Most studies of the pharmacological treatment of depression in SAD have involved SSRIs. Two large, randomized, controlled studies using fluoxetine (Prozac) and sertraline (Zoloft) have shown that treatment response is consistent with the response observed in nonseasonal depression (Lam et al., 1995; Moscovitch et al., 2004). A recent comparison of medication (fluoxetine) and light (10,000-lux fluorescent box) demonstrated no difference in response rate to both treatments, in the range of 60% (Lam et al., in press). A smaller study of sertraline and bright light therapy showed similar benefits of both treatments (Ruhrmann et al., 1998). Buproprion (Wellbutrin) and tranylcypromine (Parnate) have shown positive effects in small open trials (Dilsaver and Jaeckle, 1990; Dilsaver et al., 1992). There are some very limited controlled data suggesting moclobemide (Aurorix) may be effective (Lingjaerde et al., 1993; Partonen and Lonnqvist, 1996).

Several nontraditional antidepressant medications have been investigated. A small open trial has shown benefit for modafinil (Provigil) (Lundt, 2003). The use of melatonin was found not beneficial in a several studies (Danilenko and Putilov, 2005; Wirz-Justice et al., 1990), however, preliminary data from a larger controlled study have been positive (Lewy et al., 1998a). Beta-blockers (Rosenthal et al., 1988; Schlager, 1994), L-tryptophan (Ghadirian et al., 1998; McGrath et al., 1990) and St. Johns wort (Hypericum perforatum) (Martinez et al., 1994) have been investigated, with mixed results.

It is reasonable to consider patients with little reverse vegetative symptoms, moderate-to-severe depression and older age for treatment with an SSRI before considering light therapy. An adequate trial of treatment should last approximately six weeks at doses used in the treatment of nonseasonal depression (Lam and Levitt, 1999). For patients who are refractory or partially responsive to an adequate trial of light therapy, it is reasonable to consider either augmentation or switching to an SSRI. Similarly, for patients who are refractory or partially responsive to an SSRI, it is reasonable to consider a trial of light therapy augmentation or switching to light monotherapy.

Novel Treatments

Various other treatments have been investigated in the treatment of seasonal depression. In 1998, Terman et al. discovered that high-density, negative air ion exposure was equally effective as bright light therapy in a controlled, crossover design trial. The high-density, negative air ion exposure was superior to low-density, negative air ion exposure.

The effect of exercise on mood has been investigated. Interestingly, there are some unreplicated data that show one week of one-hour, morning walks can improve symptoms (Wirz-Justice et al., 1996). Therefore, it is possible that a combination of increasing natural light exposure and exercise may be beneficial.

Very little data exist on the psychotherapeutic management of SAD. There has been great advancement in the evidence base for certain psychotherapeutic modalities in the treatment of depression and a relative paucity of literature looking at seasonal depression. A preliminary analysis of an ongoing randomized, controlled trial investigating cognitive-behavioral therapy (CBT) versus light therapy has shown promising results (Rohan et al., 2003). The role of CBT as a first-line agent or an adjunct is yet to be determined, but it is likely that CBT will have a similar role in SAD as it does in the treatment of major depression.

Conclusion

Seasonal affective disorder is a well-defined subtype of depression. Delineating the etiology and pathogenesis of this subtype of depression is still in its early stages. Light therapy is a very effective treatment with clearly defined parameters. Timing and duration of treatment require further evidence. There is emerging evidence on the role of combining light therapy with pharmacological treatment. The bulk of data suggest that first-line therapies for nonseasonal depression are effective in the seasonal subtype; however, SSRIs are the only well-validated class of medications that have been studied.

Disclosures:

Dr. Blumberger is a resident in the department of psychiatry at the University of Toronto.

Dr. Levitt is a research fellow in the department of psychiatry at the University of Toronto. He is also president of the Society for Light Treatment and Biological Rhythms.

References:

Avery DH, Eder DN, Bolte MA et al. (2001), Dawn simulation and bright light in the treatment of SAD: a controlled study. Biol Psychiatry 50(3):205-216.

Bauer MS, Kurtz JW, Rubin LB, Marcus JG (1994), Mood and behavioral effects of four-week light treatment in winter depressives and controls. J Psychiatr Res 28(2):135-145.

Blazer DG, Kessler RC, Swartz MS (1998), Epidemiology of recurrent major and minor depression with a seasonal pattern. The National Comorbidity Survey. Br J Psychiatry 172:164-167 [see comment].

Brewerton TD, Berrettini WH, Nurnberger JI Jr, Linnoila M (1988), Analysis of seasonal fluctuations of CSF monoamine metabolites and neuropeptides in normal controls: findings with 5HIAA and HVA. Psychiatry Res 23(3):257-265.

Chan PK, Lam RW, Perry KF (1994), Mania precipitated by light therapy for patients with SAD. J Clin Psychiatry 55(10):454 [letter].

Danilenko KV, Putilov AA (2005), Melatonin treatment of winter depression following total sleep deprivation: waking EEG and mood correlates. Neuropsychopharmacology 30(7):1345-1352.

Dilsaver SC, Jaeckle RS (1990), Winter depression responds to an open trial of tranylcypromine. J Clin Psychiatry 51(8):326-329.

Dilsaver SC, Qamar AB, Del Medico VJ (1992), The efficacy of bupropion in winter depression: results of an open trial. J Clin Psychiatry 53(7):252-255.

Eastman CI, Young MA, Fogg LF et al. (1998), Bright light treatment of winter depression: a placebo-controlled trial. Arch Gen Psychiatry 55(10):883-889 [see comments].

Ghadirian AM, Murphy BE, Gendron MJ (1998), Efficacy of light versus tryptophan therapy in seasonal affective disorder. J Affect Disord 50(1):23-27.

Golden RN, Gaynes BN, Ekstrom RD et al. (2005), The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry 162(4):656-662.

Joffe RT, Moul DE, Lam RW et al. (1993), Light visor treatment for seasonal affective disorder: a multicenter study. Psychiatry Res 46(1):29-39.

Johansson C, Smedh C, Partonen T et al. (2001), Seasonal affective disorder and serotonin-related polymorphisms. Neurobiol Dis 8(2):351-357.

Lam RW, Buchanan A, Mador JA et al. (1992), The effects of ultraviolet-A wavelengths in light therapy for seasonal depression. J Affect Disord 24(4):237-243.

Lam RW, Gorman CP, Michalon M et al. (1995), Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. Am J Psychiatry 152(12):1765-1770.

Lam RW, Levitt AJ, eds. (1999), Canadian Consensus Guidelines for the Treatment of Seasonal Affective Disorder. Vancouver, B.C., Canada: Clinical & Academic Publishing.

Lam RW, Levitt AJ, Levitan RD (in press), The CAN-SAD study: randomized controlled trial of light therapy and fluoxetine in patients with winter seasonal affective disorder.

Lam RW, Zis AP, Grewal A et al. (1996), Effects of rapid tryptophan depletion in patients with seasonal affective disorder in remission after light therapy. Arch Gen Psychiatry 53(1):41-44.

Levitan RD (2005), What is the optimal implementation of bright light therapy for seasonal affective disorder (SAD)? J Psychiatry Neurosci 30(1):72.

Levitt AJ, Boyle MH (2002), The impact of latitude on the prevalence of seasonal depression. Can J Psychiatry 47(4):361-367.

Levitt AJ, Joffe RT, Moul DE et al. (1993), Side effects of light therapy in seasonal affective disorder. Am J Psychiatry 150(4):650-652 [see comment].

Levitt AJ, Wesson VA, Joffe RT et al. (1996), A controlled comparison of light box and head-mounted units in the treatment of seasonal depression. J Clin Psychiatry 57(3):105-110.

Lewy AJ, Bauer VK, Cutler NL, Sack RL (1998a), Melatonin treatment of winter depression: a pilot study. Psychiatry Res 77(1):57-61.

Lewy AJ, Bauer VK, Cutler NL et al. (1998b), Morning vs evening light treatment of patients with winter depression. Arch Gen Psychiatry 55(10):890-896 [see comments].

Lewy AJ, Sack RL (1988), The phase-shift hypothesis of seasonal affective disorder. Am J Psychiatry 145(8):1041-1043 [letter].

Lingjaerde O, Reichborn-Kjennerud T, Haggag A et al. (1993), Treatment of winter depression in Norway. II. A comparison of the selective monoamine oxidase A inhibitor moclobemide and placebo. Acta Psychiatr Scand 88(5):372-380.

Lundt L (2003), Modafinil improves winter depression in a pilot study. Chronobiol Int 20(6):1217.

Martinez B, Kasper S, Ruhrmann S, Moller HJ (1994), Hypericum in the treatment of seasonal affective disorders. J Geriatr Psychiatry Neurol 7(suppl 1):S29-S33.

Martiny K, Lunde M, Simonsen C et al. (2004), Relapse prevention by citalopram in SAD patients responding to 1 week of light therapy. A placebo-controlled study. Acta Psychiatr Scand 109(3):230-234.

McGrath RE, Buckwald B, Resnick EV (1990), The effect of L-tryptophan on seasonal affective disorder. J Clin Psychiatry 51(4):162-163.

Meesters Y, Beersma DG, Bouhuys AL et al. (1999), Prophylactic treatment of seasonal affective disorder (SAD) by using light visors: bright white or infrared light? Biol Psychiatry 46(2):239-246.

Moscovitch A, Blashko CA, Eagles JM et al. (2004), A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. Psychopharmacology (Berl) 171(4):390-397.

Neumeister A, Praschak-Rieder N, Hesselmann B et al. (1997), Rapid tryptophan depletion in drug-free depressed patients with seasonal affective disorder. Am J Psychiatry 154(8):1153-1155.

Oren DA, Moul DE, Schwartz PJ et al. (1994), A controlled trial of levodopa plus carbidopa in the treatment of winter seasonal affective disorder: a test of the dopamine hypothesis. J Clin Psychopharmacol 14(3):196-200.

Partonen T, Lonnqvist J (1996), Moclobemide and fluoxetine in treatment of seasonal affective disorder. J Affect Disord 41(2):93-99.

Rohan KJ, Tierney-Lindsey K, Roecklein KA et al. (2003), Cognitive-behavioural and light treatments for seasonal affective disorder: interim analyses from a controlled randomized clinical trial. Chronobiol Int 20(6):1219.

Rosen LN, Targum SD, Terman M et al. (1990), Prevalence of seasonal affective disorder at four latitudes. Psychiatry Res 31(2):131-144.

Rosenthal NE, Jacobsen FM, Sack DA et al. (1988), Atenolol in seasonal affective disorder: a test of the melatonin hypothesis. Am J Psychiatry 145(1):52-56.

Rosenthal NE, Mazzanti CM, Barnett RL et al. (1998), Role of serotonin transporter promoter repeat length polymorphism (5-HTTLPR) in seasonality and seasonal affective disorder. Mol Psychiatry 3(2):175-177.

Rosenthal NE, Rotter A, Jacobsen FM, Skwerer RG (1987), No mood-altering effects found after treatment of normal subjects with bright light in the morning. Psychiatry Res 22(1):1-9.

Rosenthal NE, Sack DA, Gillin JC et al. (1984), Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry 41(1):72-80.

Rudorfer MV, Skwerer RG, Rosenthal NE (1993), Biogenic amines in seasonal affective disorder: effects of light therapy. Psychiatry Res 46(1):19-28.

Ruhrmann S, Kasper S, Hawellek B et al. (1998), Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. Psychol Med 28(4):923-933.

Schlager DS (1994), Early-morning administration of short-acting beta blockers for treatment of winter depression. Am J Psychiatry 151(9):1383-1385.

Terman M, Terman JS, Ross DC (1998), A controlled trial of timed bright light and negative air ionization for treatment of winter depression. Arch Gen Psychiatry 55(10):875-882 [see comments].

Thalen BE, Kjellman BF, Morkrid L, Wetterberg L (1995), Seasonal and non-seasonal depression. A comparison of clinical characteristics in Swedish patients. Eur Arch Psychiatry Clin Neurosci 245(2):101-108.

Thompson C, Isaacs G (1988), Seasonal affective disorder--a British sample. Symptomatology in relation to mode of referral and diagnostic subtype. [Published erratum J Affect Disord 1990;20(4):251.] J Affect Disord 14(1):1-11.

Wehr TA, Giesen HA, Schulz PM et al. (1991), Contrasts between symptoms of summer depression and winter depression. J Affect Disord 23(4):173-183.

Wirz-Justice A, Graw P, Krauchi K et al. (1990), Morning or night-time melatonin is ineffective in seasonal affective disorder. J Psychiatr Res 24(2):129-137.

Wirz-Justice A, Graw P, Krauchi K et al. (1996), 'Natural' light treatment of seasonal affective disorder. J Affect Disord 37(2-3):109-120.